VitaNova Life Sciences director Ruiming Zhou resigns

Q: What board change did VitaNova Life Sciences (VNOV) disclose in this 8-K?

VitaNova Life Sciences disclosed that director Ruiming Zhou resigned from the board effective March 12, 2026. The company clarified the resignation was not due to disagreements over operations, policies, or practices, indicating a routine governance change rather than a reported conflict.

Q: Did VitaNova Life Sciences (VNOV) report any disagreement linked to Ruiming Zhou’s resignation?

No. VitaNova Life Sciences stated that Ms. Zhou’s resignation was not the result of any disagreements with the company regarding its operations, policies, or practices. This language is commonly used to indicate the departure is not tied to disclosed disputes.

Q: Who signed the VitaNova Life Sciences (VNOV) 8-K reporting the director resignation?

The 8-K was signed on behalf of VitaNova Life Sciences by Rose Kelly, who serves as Chief Executive Officer and Director. The signature block identifies her as the company’s principal executive officer at the time of the filing dated March 18, 2026.

Q: What is the principal office address of VitaNova Life Sciences (VNOV)?

VitaNova Life Sciences lists its principal office at 39 E Broadway, Suite 603, New York, NY 10002. The company also provides a telephone contact number of +1-516-886-8888 in the header information of the current report.

VitaNova Life Sciences Corporation reported a board change.

Accepted by SEC EDGAR 03/18/2026 - 05:00 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

VitaNova Life Sciences Corporation reported a board change. Effective March 12, 2026, Ruiming Zhou resigned from her position as a director of the company. The company states that Ms. Zhou’s resignation was not due to any disagreement regarding VitaNova’s operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did VitaNova Life Sciences (VNOV) disclose in this 8-K?

VitaNova Life Sciences disclosed that director Ruiming Zhou resigned from the board effective March 12, 2026. The company clarified the resignation was not due to disagreements over operations, policies, or practices, indicating a routine governance change rather than a reported conflict.

When did Ruiming Zhou’s resignation from VitaNova Life Sciences (VNOV) take effect?

Ruiming Zhou’s resignation as a director of VitaNova Life Sciences became effective on March 12, 2026. This date marks the official change in the company’s board composition as reported in the current report on Form 8-K filed under Item 5.02.

Did VitaNova Life Sciences (VNOV) report any disagreement linked to Ruiming Zhou’s resignation?

No. VitaNova Life Sciences stated that Ms. Zhou’s resignation was not the result of any disagreements with the company regarding its operations, policies, or practices. This language is commonly used to indicate the departure is not tied to disclosed disputes.

What is the trading symbol and market for VitaNova Life Sciences common stock?

VitaNova Life Sciences’ common stock trades under the symbol VNOV on the OTC Pink Sheets. This designation indicates the shares are quoted on the OTC market rather than a national securities exchange such as the NYSE or Nasdaq.

Who signed the VitaNova Life Sciences (VNOV) 8-K reporting the director resignation?

The 8-K was signed on behalf of VitaNova Life Sciences by Rose Kelly, who serves as Chief Executive Officer and Director. The signature block identifies her as the company’s principal executive officer at the time of the filing dated March 18, 2026.

What is the principal office address of VitaNova Life Sciences (VNOV)?

VitaNova Life Sciences lists its principal office at 39 E Broadway, Suite 603, New York, NY 10002. The company also provides a telephone contact number of +1-516-886-8888 in the header information of the current report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 12, 2026

VitaNova Life Sciences Corporation

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-218733		35-2583762
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

39 E Broadway, Suite 603, New York, NY 10002

(Address of principal office)

+1-516-886-8888

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		VNOV		OTC Pink Sheets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of March 12, 2026, Ruiming Zhou resigned from her position as the director of VitaNova Life Sciences Corporation (the “Company”). Ms. Zhou’s resignation was not a result of any disagreements with the Company on any matter relating to its operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2026

VitaNova Life Sciences Corporation


By:	/s/ Rose Kelly
	Rose Kelly
	Chief Executive Officer and Director (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents